Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 4,234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

NCT03740724
View directory record Official record
Conditions
Morphea, Scleroderma, Localized, Scleroderma
Interventions
FCX-013, veledimex
Genetic · Drug
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Not applicable Interventional

Decreasing Antibiotic Prescribing in Acute Respiratory Infections Through Nurse Driven Clinical Decision Support

NCT04255303
View directory record Official record
Conditions
Acute Respiratory Infection
Interventions
Integrated clinical prediction rule (iCPR) system (iCPR)
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
New York, New York • Salt Lake City, Utah • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study to Evaluate BMS-830216 in Healthy Subjects

NCT00878020
View directory record Official record
Conditions
Obesity
Interventions
BMS-830216, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 23, 2026, 1:33 PM EDT
Recruiting Not applicable Interventional

Smartphone Services for Stimulant Use Disorder

NCT07092059
View directory record Official record
Conditions
Stimulant Use Disorder
Interventions
Smartphone digital therapeutic system
Device
Lead sponsor
DynamiCare Health
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)

NCT00705003
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone), Matching placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

NCT01754818
View directory record Official record
Conditions
Healthy
Interventions
Bendavia 10mg, Bendavia 50mg, Bendavia 100mg, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

NCT01841996
View directory record Official record
Conditions
Onychomycosis
Interventions
ME1111 solution, Vehicle Solution
Drug
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 23, 2026, 1:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

NCT05322590
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

V2 Receptor Effects on Fluid Regulation and Performance

NCT02084797
View directory record Official record
Conditions
Electrolyte Imbalance, Hyponatremia, Hypernatremia
Interventions
V2R (Vasopressin 2 receptor)
Drug
Lead sponsor
Oakland University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Michigan
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 2 Interventional

RE104 Safety and Efficacy Study in Postpartum Depression

NCT06342310
View directory record Official record
Conditions
Postpartum Depression
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Tucson, Arizona • Santa Monica, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 1:33 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Novel Oral Natural Extract for the Treatment of Senile Purpura

NCT01183910
View directory record Official record
Conditions
PURPURA
Interventions
Citrus Bioflavanoid Blend, Calcium Carbonate
Dietary Supplement
Lead sponsor
Nexgen Dermatologics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 3 Interventional

Multidisciplinary Approach to Reduce Injury and Substance Abuse

NCT01048359
View directory record Official record
Conditions
Drug Abuse
Interventions
Brief advice, Brief Intervention plus Booster, Brief Intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01378676
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
San Francisco, California • Jacksonville, Florida • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 23, 2026, 1:33 PM EDT
Terminated Phase 2 Interventional Results available

The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment

NCT01655823
View directory record Official record
Conditions
Pain, Peripheral Neuropathy, Neuropathic Pain
Interventions
Placebo, Tetrodotoxin
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 23, 2026, 1:33 PM EDT
Terminated Phase 1Phase 2 Interventional

Default BP Medication Intensification

NCT01994408
View directory record Official record
Conditions
Hypertension
Interventions
default intensification
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 4 Interventional

Benefit of Elevation of HDL-C in Women

NCT01921010
View directory record Official record
Conditions
Cardiovascular Outcomes
Interventions
Niaspan, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 23, 2026, 1:33 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Oral Contraception Under Simulated OTC Conditions

NCT03559010
View directory record Official record
Conditions
Contraception
Interventions
Norgestrel 0.075 mg tablets
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
12 Years and older · Female only
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
44
States / cities
Birmingham, Alabama • Homewood, Alabama • McCalla, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 23, 2026, 1:33 PM EDT
Terminated Not applicable Interventional Results available

Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects

NCT01924182
View directory record Official record
Conditions
Chronic Pain
Interventions
SynchroMed Infusion System and Intrathecal Morphine Sulfate, Conventional Medicine
Device · Other
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Homewood, Alabama • Napa, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 23, 2026, 1:33 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis

NCT05092646
View directory record Official record
Conditions
Ankle Osteoarthritis
Interventions
Axolotl Ambient, "Drug/Placebo: 0.9% Normal Saline"
Biological · Drug
Lead sponsor
Axolotl Biologix
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Boise, Idaho • Shreveport, Louisiana • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 1:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score

NCT07020546
View directory record Official record
Conditions
Infertility, Poor Ovarian Reserve, Embryo Growth Disorder, in Vitro Fertilization
Interventions
Ovarian Platelet-rich plasma (PRP) injections
Procedure
Lead sponsor
Generation Next Fertility
Other
Eligibility
18 Years to 47 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

NCT06097676
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention

NCT03855410
View directory record Official record
Conditions
Tobacco Use, Drug Use, Adolescent Behavior, Alcohol Use, Sexual Risk Behavior
Interventions
S4E, Attention-Matched Control Group
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Ann Arbor, Michigan • Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)

NCT00299546
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Golimumab 50 mg, Golimumab 100 mg
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 23, 2026, 1:33 PM EDT